BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
32 hedge funds and large institutions have $6.72M invested in BRAINSTORM CELL THERAPUTC in 2017 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 7 closing their positions.
600% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 1
86% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 7
82% more call options, than puts
Call options by funds: $289K | Put options by funds: $159K
23% more funds holding
Funds holding: 26 → 32 (+6)
0.27% less ownership
Funds ownership: 0.85% → 0.58% (-0.27%)
27% less capital invested
Capital invested by funds: $9.23M → $6.72M (-$2.51M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
+$216K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$155K |
| 3 |
Renaissance Technologies
New York
|
+$99.5K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$98.9K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$88.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.76M |
| 2 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
-$471K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$70K |
| 4 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
-$25K |
| 5 |
BlackRock
New York
|
-$7.05K |
BCLI Hedge Fund Activity: Q3 2017 in Review
32 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q3 2017, worth a combined $6.72M — down 27% from $9.23M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new BCLI positions and 7 closed out — a net gain of 6 holders — while 7 added to existing stakes and 1 trimmed.
The largest buyer was CIBC Private Wealth Group, opening a new position worth an estimated $216K. The largest seller was Sphera Funds Management, exiting entirely with an estimated $2.76M sold.
- 32 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q3 2017, up from 26 in Q2 2017.
- Funds reported $6.72M of BRAINSTORM CELL THERAPUTC stock for Q3 2017, down 27% quarter-over-quarter.
- 13 funds opened new BRAINSTORM CELL THERAPUTC positions in Q3 2017 and 7 closed out, a net change of +6 holders.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q3 2017 was CIBC Private Wealth Group, an estimated $216K added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q3 2017 was Sphera Funds Management, an estimated $2.76M sold.
Based on aggregated 13F filings for Q3 2017.